Compositions and methods for producing bacterial conjugate vaccines
Longer chain antigenic O-polysaccharide chains for use as a hapten in conjugate vaccines can be produced in a controlled manner using recombinant Gram-negative bacteria that overexpress native or heterologous genes of the wzz family, for example wzzB. Bacteria expressing a chosen wzz gene have modified O-polysaccharide chain lengths, allowing the bacteria to produce lipopolysaccharides having the longer O-polysaccharides. The LPS produced by the bacteria can be hydrolyzed to form core-O-polysaccharide molecules that can be conjugated to a carrier molecule, for example flagellin, to produce a vaccine. The invention also provides recombinant bacteria producing the longer chain O-polysaccharides, the polysaccharide molecules, themselves, conjugated vaccines comprising the O-polysaccharides, pharmaceutical compositions and kits.
1. A Salmonella enterica serotype Typhimurium CVD 1925 core-O-polysaccharide hapten purified from Salmonella enterica serotype Typhimurium CVD 1925 which overexpresses a Salmonella enterica serotype Typhimurium wzz family protein.
2. The core-O-polysaccharide hapten of claim 1 , wherein the wzz family protein is wzzB.
3. The core-O-polysaccharide hapten of claim 1 , further comprising a carrier protein.
4. The conjugate or complexed vaccine of claim 3 , wherein the core-O-polysaccharide hapten is covalently linked or complexed to a carrier protein.
5. The conjugate or complexed vaccine of claim 3 , wherein the core-O-polysaccharide hapten and the carrier protein are chemically conjugated or complexed using a cross-linker or polymer.
6. The conjugate vaccine of claim 3 , wherein the carrier protein is from a homologous bacterial strain or a heterologous bacterial strain.
7. The conjugate vaccine of claim 3 , wherein the carrier protein is flagellin and selected from the group consisting of flagellin A, flagellin B, phase 1 flagella protein, and phase 2 flagella protein.
8. The conjugate vaccine of claim 7 , wherein the flagellin is from the homologous or a heterologous species as the core-O-polysaccharide hapten.
9. The core-O-polysaccharide hapten of claim 1 , formulated as a conjugate vaccine or a complexed vaccine.